RecruitingNCT04353557

ctDNA Monitoring in Early Breast Cancer

Monitoring Circulating Tumor DNA in Patients With Early Stage Breast Cancer

Sponsor

Geneplus-Beijing Co. Ltd.

Enrollment

200 participants

Start Date

Nov 29, 2019

Study Type

OBSERVATIONAL

Conditions

Breast Cancer

Summary

This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria7

Patients aged 18 to 80 years old
Histologically proven primary breast cancer with clinical stage I-III
Patients with neoadjuvant therapy, and/or radical surgery/breast conserving surgery, adjuvant chemotherapy and target therapy (Her2+), radiotherapy (if indicated).
Expected to achieve R0 resection.
Estimated lifetime is more than 3 months.
Signed Informed Consent Form
Consent to provide research blood samples.

Exclusion Criteria4

Patients intended to receive adjuvant chemotherapy with Eastern Cooperative Oncology Group (ECOG) performance status 3, 4 or 5.
Patients intended to receive postoperative radiotherapy with Eastern Cooperative Oncology Group (ECOG) performance status 5.
Prior diagnosis of cancer in the previous 5 years, other than for basal cell carcinoma of the skin or cervical carcinoma in situ.
Presence of any systemic illness incompatible with participation in the clinical trial or inability to provide written informed consent.